Kayne Anderson Rudnick Investment Management
CNTA

Kayne Anderson Rudnick Investment Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-80
Closed -$1K – 616
2022
Q1 		$1K Buy
+80
New +$729 ﹤0.01% 622

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CNTA Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2022, closing a stake of 80 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in CNTA in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 41 funds tracked by Wall St. Rank hold CNTA as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Centessa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 80 Centessa Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Centessa Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Centessa Pharmaceuticals position peaked at $1K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.